Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial

D.H. Lee

Department of Dermatology, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul 110-744, Korea

Search for more papers by this author

K. Li,

K. Li

Department of Dermatology, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul 110-744, Korea

Search for more papers by this author

D.H. Suh,

D.H. Suh

Department of Dermatology, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul 110-744, Korea

Search for more papers by this author

D.H. Lee,

D.H. Lee

Department of Dermatology, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul 110-744, Korea

Search for more papers by this author

K. Li,

K. Li

Department of Dermatology, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul 110-744, Korea

Search for more papers by this author

D.H. Suh,

D.H. Suh

Department of Dermatology, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul 110-744, Korea

Search for more papers by this author

First published: 20 March 2008

https://doi.org/10.1111/j.1365-2133.2008.08496.x

Citations: 32

Dae Hun Suh.
E-mail: [email protected]

Conflicts of interest
None declared.

Share a link

Email
Wechat
Bluesky

Summary

Background Steroid-induced rosacea is a relatively common dermatosis that is caused by the prolonged application of topical steroid to the face.

Objectives The purpose of this investigator-blind, split-face study was to evaluate the efficacy and safety of pimecrolimus 1% cream for the treatment of steroid-induced rosacea.

Patients/methods Patients were instructed to apply pimecrolimus 1% cream twice daily to the involved areas of a randomly allocated half side for the first 2 weeks, and to follow this by applying pimecrolimus 1% cream to both sides for a further 6 weeks.

Results Fifteen of the 18 patients completed the 8-week study. After 1 week of application, a statistically significant improvement was observed for investigator’s global assessments of erythema and papules on prior-treated sides (P-side). Later-treated sides (L-side) showed subsequent improvement after use of pimecrolimus on the L-side. Likewise, a statistically significant improvement was also observed for numbers of papules/pustules on P-sides after 1 week, and L-sides showed a significant improvement after application of pimecrolimus on the L-side. Comparative reflectance colorimetric assessments revealed that ΔL*, Δa* and Δb* tended to converge to zero during the first 4 weeks. A statistically significant improvement was observed for percentage area affected on P-sides after 1 week of application. The L-side showed a significant improvement after use of pimecrolimus cream on that side. The visual analogue scale of P-sides decreased more rapidly than those of L-sides. Cutaneous side-effects were mild and transient.

Conclusions This study suggests that pimecrolimus 1% cream is an effective and well-tolerated treatment for steroid-induced rosacea.

References

1 Sneddon I. Iatrogenic dermatitis. Br Med J 1969; 4: 49.
10.1136/bmj.4.5674.49-a
PubMed Web of Science® Google Scholar
2 Leyden JJ, Thew M, Kligman AM. Steroid rosacea. Arch Dermatol 1974; 110: 619–22.
10.1001/archderm.1974.01630100075019
CAS PubMed Web of Science® Google Scholar
3 Ljubojeviae S, Basta-Juzbasiae A, Lipozeneiae J. Steroid dermatitis resembling rosacea: aetiopathogenesis and treatment. J Eur Acad Dermatol Venereol 2002; 16: 121–6.
10.1046/j.1468-3083.2002.00388_2.x
CAS PubMed Web of Science® Google Scholar
4 Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003; 17: 493–503.
10.1046/j.1468-3083.2003.00692.x
CAS PubMed Web of Science® Google Scholar
5 Meurer M, Folster-Holst R, Wozel G et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002; 205: 271–7.
10.1159/000065863
CAS PubMed Web of Science® Google Scholar
6 Berger TG, Duvic M, Van Voorhees AS et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006; 54: 818–23.
10.1016/j.jaad.2006.01.054
PubMed Web of Science® Google Scholar
7 Pabby A, An KP, Laws RA. Combination therapy of tetracycline and tacrolimus resulting in rapid resolution of steroid-induced periocular rosacea. Cutis 2003; 72: 141–2.
PubMed Web of Science® Google Scholar
8 Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol 2001; 44: 995–8.
10.1067/mjd.2001.114739
CAS PubMed Web of Science® Google Scholar
9 Meykadeh N, Meiss F, Marsch WC, Fischer M. [Steroid-aggravated rosacea: successful therapy with pimecrolimus]. Hautarzt 2007; 58: 338–42 [in German].
10.1007/s00105-006-1179-7
CAS PubMed Web of Science® Google Scholar
10 Chu CY. The use of 1% pimecrolimus cream for the treatment of steroid-induced rosacea. Br J Dermatol 2005; 152: 396–9.
10.1111/j.1365-2133.2005.06404.x
PubMed Web of Science® Google Scholar
11 Antille C, Saurat JH, Lubbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol 2004; 140: 457–60.
10.1001/archderm.140.4.457
PubMed Web of Science® Google Scholar
12 Bernard LA, Cunningham BB, Al-Suwaidan S et al. A rosacea-like granulomatous eruption in a patient using tacrolimus ointment for atopic dermatitis. Arch Dermatol 2003; 139: 229–31.
10.1001/archderm.139.2.229
PubMed Web of Science® Google Scholar
13 El Sayed F, Ammoury A, Dhaybi R et al. Rosaceiform eruption to pimecrolimus. J Am Acad Dermatol 2006; 54: 548–50.
10.1016/j.jaad.2005.04.053
PubMed Web of Science® Google Scholar
14 Gorman CR, White SW. Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream. Arch Dermatol 2005; 141: 1168.
10.1001/archderm.141.9.1168
PubMed Web of Science® Google Scholar
15 Lubbe J, Stucky L, Saurat JH. Rosaceiform dermatitis with follicular Demodex after treatment of facial atopic dermatitis with 1% pimecrolimus cream. Dermatology 2003; 207: 204–5.
10.1159/000071800
PubMed Web of Science® Google Scholar
16 Gupta AK, Chaudhry MM. Critical review of the manner in which the efficacy of therapies for rosacea are evaluated. Int J Dermatol 2003; 42: 909–16.
10.1046/j.1365-4362.2003.01861.x
PubMed Web of Science® Google Scholar
17 Gessert CE, Bamford JT. Measuring the severity of rosacea: a review. Int J Dermatol 2003; 42: 444–8.
10.1046/j.1365-4362.2003.01780.x
PubMed Web of Science® Google Scholar
18 Weatherall IL, Coombs BD. Skin color measurements in terms of CIELAB color space values. J Invest Dermatol 1992; 99: 468–73.
10.1111/1523-1747.ep12616156
CAS PubMed Web of Science® Google Scholar
19 Hermanns JF, Pierard GE. High-resolution epiluminescence colorimetry of striae distensae. J Eur Acad Dermatol Venereol 2006; 20: 282–7.
10.1111/j.1468-3083.2006.01426.x
CAS PubMed Web of Science® Google Scholar
20 Seitz JC, Whitmore CG. Measurement of erythema and tanning responses in human skin using a tri-stimulus colorimeter. Dermatologica 1988; 177: 70–5.
10.1159/000248520
CAS PubMed Web of Science® Google Scholar
21 Ghersetich I, Brazzini B, Peris K et al. Pyruvic acid peels for the treatment of photoaging. Dermatol Surg 2004; 30: 32–6; discussion 6.
10.1111/j.1524-4725.2004.30002.x
CAS PubMed Web of Science® Google Scholar
22 Pershing LK, Reilly CA, Corlett JL et al. Assessment of pepper spray product potency in Asian and Caucasian forearm skin using transepidermal water loss, skin temperature and reflectance colorimetry. J Appl Toxicol 2006; 26: 88–97.
10.1002/jat.1113
CAS PubMed Web of Science® Google Scholar
23 Fisher AA. Steroid rosacea: a friendly pharmacist syndrome. Cutis 1987; 40: 209–11.
CAS PubMed Web of Science® Google Scholar
24 Litt JZ. Steroid-induced rosacea. Am Fam Physician 1993; 48: 67–71.
CAS PubMed Web of Science® Google Scholar
25 Rapaport MJ, Rapaport V. Eyelid dermatitis to red face syndrome to cure: clinical experience in 100 cases. J Am Acad Dermatol 1999; 41: 435–42.
10.1016/S0190-9622(99)70118-0
CAS PubMed Web of Science® Google Scholar
26 Bamford JT, Elliott BA, Haller IV. Tacrolimus effect on rosacea. J Am Acad Dermatol 2004; 50: 107–8.
10.1016/S0190-9622(03)02157-1
PubMed Web of Science® Google Scholar
27 Gisondi P, Ellis CN, Girolomoni G. Pimecrolimus in dermatology: atopic dermatitis and beyond. Int J Clin Pract 2005; 59: 969–74.
10.1111/j.1368-5031.2005.00587.x
CAS PubMed Web of Science® Google Scholar
28 Eichenfield LF, Lucky AW, Boguniewicz M et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46: 495–504.
10.1067/mjd.2002.122187
PubMed Web of Science® Google Scholar
29 Meurer M, Fartasch M, Albrecht G et al. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004; 208: 365–72.
10.1159/000078462
PubMed Web of Science® Google Scholar
30 Rigopoulos D, Ioannides D, Kalogeromitros D et al. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br J Dermatol 2004; 151: 1071–5.
10.1111/j.1365-2133.2004.06208.x
CAS PubMed Web of Science® Google Scholar
31 Firooz A, Solhpour A, Gorouhi F et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol 2006; 142: 1066–7.
10.1001/archderm.142.8.1066
PubMed Web of Science® Google Scholar
32 Crawford KM, Russ B, Bostrom P. Pimecrolimus for treatment of acne rosacea. Skinmed 2005; 4: 147–50.
10.1111/j.1540-9740.2005.03740.x
PubMed Web of Science® Google Scholar
33 Kreuter A, Gambichler T, Breuckmann F et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51: 407–10.
10.1016/j.jaad.2004.01.044
PubMed Web of Science® Google Scholar
34 Takiwaki H, Serup J. Measurement of color parameters of psoriatic plaques by narrow-band reflectance spectrophotometry and tristimulus colorimetry. Skin Pharmacol 1994; 7: 145–50.
10.1159/000211289
CAS PubMed Web of Science® Google Scholar
35 Horiuchi Y, Bae SJ, Katayama I. FK506 (tacrolimus) inhibition of intracellular production and enhancement of interleukin 1alpha through glucocorticoid application to chemically treated human keratinocytes. Skin Pharmacol Physiol 2005; 18: 241–6.
10.1159/000086670
CAS PubMed Web of Science® Google Scholar
36 Conde M, Andrade J, Bedoya FJ et al. Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect on nitric oxide synthase activity. Immunology 1995; 84: 476–81.
CAS PubMed Web of Science® Google Scholar
37 Neckermann G, Bavandi A, Meingassner JG. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br J Dermatol 2000; 142: 669–79.
10.1046/j.1365-2133.2000.03411.x
CAS PubMed Web of Science® Google Scholar
38 Lan CC, Kao YH, Huang SM et al. FK506 independently upregulates transforming growth factor beta and downregulates inducible nitric oxide synthase in cultured human keratinocytes: possible mechanisms of how tacrolimus ointment interacts with atopic skin. Br J Dermatol 2004; 151: 679–84.
10.1111/j.1365-2133.2004.06109.x
CAS PubMed Web of Science® Google Scholar
39 Sugita T, Tajima M, Tsubuku H et al. A new calcineurin inhibitor, pimecrolimus, inhibits the growth of Malassezia spp. Antimicrob Agents Chemother 2006; 50: 2897–8.
10.1128/AAC.00687-06
CAS PubMed Web of Science® Google Scholar
40 Meingassner JG, Fahrngruber H, Bavandi A. Pimecrolimus inhibits the elicitation phase but does not suppress the sensitization phase in murine contact hypersensitivity, in contrast to tacrolimus and cyclosporine A. J Invest Dermatol 2003; 121: 77–80.
10.1046/j.1523-1747.2003.12331.x
CAS PubMed Web of Science® Google Scholar
41 Baima B, Sticherling M. Demodicidosis revisited. Acta Derm Venereol 2002; 82: 3–6.
10.1080/000155502753600795
CAS PubMed Web of Science® Google Scholar
42 Meingassner JG, Aschauer H, Stuetz A et al. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp Dermatol 2005; 14: 752–7.
10.1111/j.1600-0625.2005.00354.x
CAS PubMed Web of Science® Google Scholar
43 Draelos Z, Nayak A, Pariser D et al. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol 2005; 53: 602–9.
10.1016/j.jaad.2005.06.013
PubMed Web of Science® Google Scholar

Citing Literature

Volume158, Issue5

May 2008

Pages 1069-1076

Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial

Summary

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Pimecrolimus 1% cream for the treatment of steroid-induced rosacea: an 8-week split-face clinical trial

Summary

References

Citing Literature

References

Related

Information